These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 23607532)

  • 1. Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn's disease.
    Liu C; Xia X; Wu W; Wu R; Tang M; Chen T; Xu F; Cong Y; Xu X; Liu Z
    Clin Exp Immunol; 2013 Jul; 173(1):102-11. PubMed ID: 23607532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-TNF Therapy Induces CD4+ T-Cell Production of IL-22 and Promotes Epithelial Repairs in Patients With Crohn's Disease.
    Fang L; Pang Z; Shu W; Wu W; Sun M; Cong Y; Liu Z
    Inflamm Bowel Dis; 2018 Jul; 24(8):1733-1744. PubMed ID: 29718341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-25 downregulates Th1/Th17 immune response in an IL-10-dependent manner in inflammatory bowel disease.
    Su J; Chen T; Ji XY; Liu C; Yadav PK; Wu R; Yang P; Liu Z
    Inflamm Bowel Dis; 2013; 19(4):720-8. PubMed ID: 23429464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy.
    Caprioli F; Bosè F; Rossi RL; Petti L; Viganò C; Ciafardini C; Raeli L; Basilisco G; Ferrero S; Pagani M; Conte D; Altomare G; Monteleone G; Abrignani S; Reali E
    Inflamm Bowel Dis; 2013; 19(4):729-39. PubMed ID: 23448791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased Th17-inducing activity of CD14+ CD163 low myeloid cells in intestinal lamina propria of patients with Crohn's disease.
    Ogino T; Nishimura J; Barman S; Kayama H; Uematsu S; Okuzaki D; Osawa H; Haraguchi N; Uemura M; Hata T; Takemasa I; Mizushima T; Yamamoto H; Takeda K; Doki Y; Mori M
    Gastroenterology; 2013 Dec; 145(6):1380-91.e1. PubMed ID: 23993972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
    Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment.
    Imaeda H; Bamba S; Takahashi K; Fujimoto T; Ban H; Tsujikawa T; Sasaki M; Fujiyama Y; Andoh A
    J Gastroenterol; 2014 Apr; 49(4):674-82. PubMed ID: 23666424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteopontin, a protein with cytokine-like properties, is associated with inflammation in Crohn's disease.
    Agnholt J; Kelsen J; Schack L; Hvas CL; Dahlerup JF; Sørensen ES
    Scand J Immunol; 2007 May; 65(5):453-60. PubMed ID: 17444956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease.
    Ricciardelli I; Lindley KJ; Londei M; Quaratino S
    Immunology; 2008 Oct; 125(2):178-83. PubMed ID: 18422560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Il-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease.
    Liu Z; Yang L; Cui Y; Wang X; Guo C; Huang Z; Kan Q; Liu Z; Liu Y
    Inflamm Bowel Dis; 2009 Aug; 15(8):1133-44. PubMed ID: 19322899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profiles of Lamina Propria T Helper Cell Subsets Discriminate Between Ulcerative Colitis and Crohn's Disease.
    Li J; Ueno A; Fort Gasia M; Luider J; Wang T; Hirota C; Jijon HB; Deane M; Tom M; Chan R; Barkema HW; Beck PL; Kaplan GG; Panaccione R; Qian J; Iacucci M; Gui X; Ghosh S
    Inflamm Bowel Dis; 2016 Aug; 22(8):1779-92. PubMed ID: 27243594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease.
    Schmitt H; Billmeier U; Dieterich W; Rath T; Sonnewald S; Reid S; Hirschmann S; Hildner K; Waldner MJ; Mudter J; Hartmann A; Grützmann R; Neufert C; Münster T; Neurath MF; Atreya R
    Gut; 2019 May; 68(5):814-828. PubMed ID: 29848778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease.
    Danese S; Sans M; Scaldaferri F; Sgambato A; Rutella S; Cittadini A; Piqué JM; Panes J; Katz JA; Gasbarrini A; Fiocchi C
    J Immunol; 2006 Feb; 176(4):2617-24. PubMed ID: 16456024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-15 receptor α expression in inflammatory bowel disease patients before and after normalization of inflammation with infliximab.
    Perrier C; Arijs I; Staelens D; Breynaert C; Cleynen I; Covens K; Ferrante M; Van Assche G; Vermeire S; de Hertogh G; Schuit F; Rutgeerts P; Ceuppens JL
    Immunology; 2013 Jan; 138(1):47-56. PubMed ID: 23039249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis.
    Rismo R; Olsen T; Cui G; Christiansen I; Florholmen J; Goll R
    Scand J Gastroenterol; 2012 May; 47(5):538-47. PubMed ID: 22486187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres.
    Tursi A; Elisei W; Picchio M; Penna A; Lecca PG; Forti G; Giorgetti G; Faggiani R; Zampaletta C; Pelecca G; Brandimarte G
    Eur J Intern Med; 2014 Jun; 25(5):485-90. PubMed ID: 24631020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An RORγt Oral Inhibitor Modulates IL-17 Responses in Peripheral Blood and Intestinal Mucosa of Crohn's Disease Patients.
    Bassolas-Molina H; Raymond E; Labadia M; Wahle J; Ferrer-Picón E; Panzenbeck M; Zheng J; Harcken C; Hughes R; Turner M; Smith D; Calderón-Gómez E; Esteller M; Carrasco A; Esteve M; Dotti I; Corraliza AM; Masamunt MC; Arajol C; Guardiola J; Ricart E; Nabozny G; Salas A
    Front Immunol; 2018; 9():2307. PubMed ID: 30405600
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease.
    Sugita S; Kawazoe Y; Imai A; Yamada Y; Horie S; Mochizuki M
    Arthritis Res Ther; 2012 May; 14(3):R99. PubMed ID: 22546542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
    Kierkus J; Dadalski M; Szymanska E; Oracz G; Wegner A; Gorczewska M; Szymanska S; Woynarowski M; Ryzko J
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):495-500. PubMed ID: 22387887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profile of soluble cytokine receptors in Crohn's disease.
    Gustot T; Lemmers A; Louis E; Nicaise C; Quertinmont E; Belaiche J; Roland S; Van Gossum A; Devière J; Franchimont D
    Gut; 2005 Apr; 54(4):488-95. PubMed ID: 15753533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.